Novo Nordisk
PulseAugur coverage of Novo Nordisk — every cluster mentioning Novo Nordisk across labs, papers, and developer communities, ranked by signal.
9 day(s) with sentiment data
-
Allbirds launches AI infrastructure business Smartbird with new CEO
Allbirds has launched a new AI infrastructure business named Smartbird, following a strategic pivot that involved selling its shoe division for $43 million and raising an additional $100 million. Nadia Carlsten, formerl…
-
Ransomware group claims 1TB data theft from Novo Nordisk, demands $25M
A ransomware group has claimed to steal over 1TB of data from pharmaceutical giant Novo Nordisk, demanding a $25 million ransom. After the company reportedly refused to pay, the group is now threatening to sell some of …
-
Hacking group extorts Novo Nordisk for $25M after data theft
A cyber extortion group claims to have stolen over 1 terabyte of data from pharmaceutical giant Novo Nordisk. The group is reportedly demanding a $25 million ransom and has threatened to sell some of the data if their d…
-
Novo Nordisk Refuses $75M Ransom Demands, Faces Data Leaks
Two distinct threat actor groups attempted to extort Novo Nordisk for $50 million and $25 million respectively. Novo Nordisk engaged with both groups but ultimately did not pay any ransom. Following these failed extorti…
-
Medicare to offer weight-loss drugs, straining doctor capacity
Starting next month, Medicare will offer weight-loss drugs like Wegovy and Zepbound for a subsidized price of $50 per month. This initiative is expected to lead to a significant surge in demand, potentially overwhelming…
-
GLP-1 Drugs Could Save Adults Hundreds of Thousands in Medical Costs
A new study from the National Bureau of Economic Research (NBER) suggests that middle-aged adults using GLP-1 drugs for obesity could save over $192,000 in lifetime medical costs. These savings are even higher for indiv…
-
Novo Nordisk hit by cyberattack stealing clinical trial data
Novo Nordisk has reported a cyberattack where hackers stole clinical trial data. The company is investigating the incident, which occurred around the same time the UK approved Wegovy for weight management. This attack h…
-
Lean Startup author Eric Ries discusses mission-driven companies
Eric Ries, author of "The Lean Startup," is discussing his new book "Incorruptible," which explores how organizations can maintain their mission over time and resist "financial gravity." He shares insights from companie…
-
Novo Nordisk CEO eyes longevity and aesthetics beyond weight loss drugs
Novo Nordisk's CEO, Mike Doustdar, is exploring new therapeutic areas beyond weight loss and diabetes, including longevity and aesthetic medicine. The company is investigating semaglutide's potential to protect vital or…
-
ASML becomes Europe's most valuable company on AI chip demand
ASML has become the most valuable company in European history, surpassing Novo Nordisk with a market capitalization of $674 billion. This surge is driven by analyst upgrades, particularly from JPMorgan and Morgan Stanle…
-
Weight loss drug coverage uncertain despite insurer formulary listings
Despite Eli Lilly's announcement that its obesity medications will be listed on the formularies of major pharmacy benefit managers, actual coverage remains uncertain. Many health insurers and plan sponsors are reluctant…
-
France to reimburse anti-obesity drugs for first time in EU
France is set to become the first European Union country to reimburse anti-obesity medications for severely obese patients starting mid-June. The government estimates this initiative will cost approximately €100 million…
-
European, US markets open; Novo Nordisk weight-loss drug plans
The article discusses the opening of European and US stock markets for the week, Novo Nordisk's strategies for its weight-loss drug, and South Korea's potential use of extraordinary tax revenues from AI-profiting compan…
-
Zuckerberg-backed AI firm acquires Parkinson's therapy from Ozempic maker
Cellular Intelligence, an AI startup funded by Mark Zuckerberg, has acquired the rights to an experimental Parkinson's cell therapy from Novo Nordisk, the pharmaceutical company known for Ozempic. This acquisition signi…
-
Open-source tool grants AI full access to pharma R&D data
An open-source project called drug-pipeline-mcp has been released, offering AI agents comprehensive access to pharmaceutical R&D data. This tool aggregates information on clinical trials, FDA/EMA approvals, safety repor…
-
Corporate America defies economic uncertainty with strong Q1 earnings
Corporate America is demonstrating resilience during the current earnings season, with a significant majority of S&P 500 companies exceeding profit expectations. This performance is occurring despite economic headwinds …
-
Seres reports 33,132 new energy vehicle sales in April, up 5.22%
Seres announced its April sales figures, reporting 33,132 new energy vehicles sold, a 5.22% increase year-over-year. For the first four months of the year, cumulative sales reached 111,632 vehicles, marking a 29.74% yea…